JP2010528091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528091A5 JP2010528091A5 JP2010509824A JP2010509824A JP2010528091A5 JP 2010528091 A5 JP2010528091 A5 JP 2010528091A5 JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010528091 A5 JP2010528091 A5 JP 2010528091A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- combination preparation
- weeks
- vinflunine
- trastuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 229960000575 trastuzumab Drugs 0.000 claims 8
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims 8
- 229960000922 vinflunine Drugs 0.000 claims 8
- 208000035269 cancer or benign tumor Diseases 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290679A EP1997534A1 (en) | 2007-05-31 | 2007-05-31 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| PCT/EP2008/056620 WO2008145697A1 (en) | 2007-05-31 | 2008-05-29 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528091A JP2010528091A (ja) | 2010-08-19 |
| JP2010528091A5 true JP2010528091A5 (enExample) | 2011-07-14 |
Family
ID=38353425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509824A Withdrawn JP2010528091A (ja) | 2007-05-31 | 2008-05-29 | ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100196363A1 (enExample) |
| EP (2) | EP1997534A1 (enExample) |
| JP (1) | JP2010528091A (enExample) |
| KR (1) | KR20100017752A (enExample) |
| CN (1) | CN101687104A (enExample) |
| AR (1) | AR066778A1 (enExample) |
| AU (1) | AU2008257555A1 (enExample) |
| BR (1) | BRPI0812280A2 (enExample) |
| CA (1) | CA2689664A1 (enExample) |
| CL (1) | CL2008001589A1 (enExample) |
| IL (1) | IL202393A0 (enExample) |
| MX (1) | MX2009012874A (enExample) |
| NO (1) | NO20093536L (enExample) |
| RU (1) | RU2009146882A (enExample) |
| TN (1) | TN2009000490A1 (enExample) |
| TW (1) | TW200908976A (enExample) |
| WO (1) | WO2008145697A1 (enExample) |
| ZA (1) | ZA200908247B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| PT4241849T (pt) | 2011-10-14 | 2024-10-30 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| AR095863A1 (es) | 2013-04-16 | 2015-11-18 | Genentech Inc | Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación |
| EP3481422A1 (en) * | 2016-07-06 | 2019-05-15 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
| MY189536A (en) | 2017-01-17 | 2022-02-16 | Hoffmann La Roche | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| EP4171748A1 (en) | 2020-06-29 | 2023-05-03 | Genentech, Inc. | Pertuzumab plus trastuzumab fixed dose combination |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
-
2007
- 2007-05-31 EP EP07290679A patent/EP1997534A1/en not_active Ceased
-
2008
- 2008-05-05 US US12/602,127 patent/US20100196363A1/en not_active Abandoned
- 2008-05-12 TW TW097117418A patent/TW200908976A/zh unknown
- 2008-05-29 JP JP2010509824A patent/JP2010528091A/ja not_active Withdrawn
- 2008-05-29 WO PCT/EP2008/056620 patent/WO2008145697A1/en not_active Ceased
- 2008-05-29 CN CN200880017406A patent/CN101687104A/zh active Pending
- 2008-05-29 AU AU2008257555A patent/AU2008257555A1/en not_active Abandoned
- 2008-05-29 BR BRPI0812280-6A2A patent/BRPI0812280A2/pt not_active IP Right Cessation
- 2008-05-29 CA CA2689664A patent/CA2689664A1/en not_active Abandoned
- 2008-05-29 EP EP08760211A patent/EP2164573A1/en not_active Withdrawn
- 2008-05-29 RU RU2009146882/15A patent/RU2009146882A/ru not_active Application Discontinuation
- 2008-05-29 KR KR1020097025793A patent/KR20100017752A/ko not_active Withdrawn
- 2008-05-29 MX MX2009012874A patent/MX2009012874A/es not_active Application Discontinuation
- 2008-05-30 CL CL2008001589A patent/CL2008001589A1/es unknown
- 2008-05-30 AR ARP080102281A patent/AR066778A1/es not_active Application Discontinuation
-
2009
- 2009-11-23 TN TNP2009000490A patent/TN2009000490A1/fr unknown
- 2009-11-23 ZA ZA200908247A patent/ZA200908247B/xx unknown
- 2009-11-29 IL IL202393A patent/IL202393A0/en unknown
- 2009-12-16 NO NO20093536A patent/NO20093536L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2608656T3 (es) | Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN | |
| JP2012067116A5 (enExample) | ||
| JP2016536352A5 (enExample) | ||
| RU2018137037A (ru) | Антинеопластические комбинации, содержащие hki-272 и винорелбин | |
| IL262988A (en) | Intentional healing | |
| JP2015512953A5 (enExample) | ||
| JP2011251975A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2019521087A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| JP2010501575A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2006503919A5 (enExample) | ||
| JP2013509444A5 (enExample) | ||
| JP2011529968A5 (enExample) | ||
| JP2009514870A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2019520426A5 (enExample) | ||
| IL299099B1 (en) | Combinations of cancer treatments | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| JP2015507020A5 (enExample) | ||
| RU2009146882A (ru) | Комбинированная противораковая терапия, включающая применение винфлунина и трастуцумаба | |
| JP2009539994A5 (enExample) | ||
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака |